MA28611B1 - Derive de purine - Google Patents

Derive de purine

Info

Publication number
MA28611B1
MA28611B1 MA29493A MA29493A MA28611B1 MA 28611 B1 MA28611 B1 MA 28611B1 MA 29493 A MA29493 A MA 29493A MA 29493 A MA29493 A MA 29493A MA 28611 B1 MA28611 B1 MA 28611B1
Authority
MA
Morocco
Prior art keywords
purine derivative
purine
derivative
Prior art date
Application number
MA29493A
Other languages
English (en)
Inventor
Philip Blatcher
Richard Peter Charles Cousins
Derek Norman Evans
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0411563A external-priority patent/GB0411563D0/en
Priority claimed from GB0509521A external-priority patent/GB0509521D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28611B1 publication Critical patent/MA28611B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MA29493A 2004-05-24 2006-11-28 Derive de purine MA28611B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0411563A GB0411563D0 (en) 2004-05-24 2004-05-24 Compounds
GB0509521A GB0509521D0 (en) 2005-05-10 2005-05-10 Compounds

Publications (1)

Publication Number Publication Date
MA28611B1 true MA28611B1 (fr) 2007-05-02

Family

ID=34968031

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29493A MA28611B1 (fr) 2004-05-24 2006-11-28 Derive de purine

Country Status (16)

Country Link
US (1) US7737126B2 (fr)
EP (1) EP1756120B1 (fr)
JP (1) JP5007225B2 (fr)
AR (1) AR049384A1 (fr)
AT (1) ATE556080T1 (fr)
AU (1) AU2005247601A1 (fr)
BR (1) BRPI0511424A (fr)
CA (1) CA2566863A1 (fr)
ES (1) ES2383604T3 (fr)
IL (1) IL179009A0 (fr)
MA (1) MA28611B1 (fr)
MX (1) MXPA06013627A (fr)
NO (1) NO20065757L (fr)
PE (1) PE20060272A1 (fr)
RU (1) RU2006141276A (fr)
WO (1) WO2005116037A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0523778D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel method
GB0523845D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel salts
WO2007061024A1 (fr) * 2005-11-25 2007-05-31 San-Apro Limited Procede pour produire un alkylfluorophosphate de sulfonium fluore
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PL2322525T3 (pl) 2006-04-21 2014-03-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
EP1889846A1 (fr) * 2006-07-13 2008-02-20 Novartis AG Dérivés de purine comme agonistes du recepteur A2a
EP1903044A1 (fr) * 2006-09-14 2008-03-26 Novartis AG Derivés de l'adénosine en tant qu' agonistes du récepteur A2A
KR20090087054A (ko) * 2006-11-10 2009-08-14 노파르티스 아게 시클로펜텐 디올 모노아세테이트 유도체

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE768925A (fr) 1970-06-30 1971-11-03 Takeda Chemical Industries Ltd Derives d'adenosine et procede de preparation
DE2034785A1 (de) 1970-07-14 1972-01-20 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Adenosin 5 carbonsäurederivate
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE789773A (fr) * 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
US3864483A (en) * 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1082695A (fr) 1972-04-10 1980-07-29 Francis E. Fischer Preparation d'adenosine-5'-carboxamides
US3966917A (en) * 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
DE2621470A1 (de) 1976-05-14 1977-12-01 Pharma Waldhof Gmbh & Co Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung
US4167565A (en) * 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
CA1239397A (fr) 1983-08-01 1988-07-19 James A. Bristol Adenosines substituee en position n.sup.6
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
DE3587717T2 (de) * 1984-04-18 1994-04-28 Whitby Research Inc N-6-thienyl-substituierte Adenosinderivate als herzgefässerweiternde Mittel.
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
CA1254888A (fr) 1984-10-26 1989-05-30 Bharat Trivedi N.sup.6-bicyclo-adenosines
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
JPH0696534B2 (ja) 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
US4767747A (en) * 1986-08-28 1988-08-30 Warner-Lambert Company Method for treating congestive heart failure with N6 -acenaphthyl adenosine
WO1988003148A2 (fr) 1986-10-31 1988-05-05 Warner-Lambert Company Derives heteroaromatiques d'adenosine
AU8276187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
NL8702926A (nl) 1986-12-15 1988-07-01 Sandoz Ag Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
FI880405A (fi) 1987-02-04 1988-08-05 Ciba Geigy Ag Adenosin-5'-karboxamidderivat.
US4962194A (en) * 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
US5219840A (en) * 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
LU87181A1 (fr) 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
US5506347A (en) 1993-02-03 1996-04-09 Gensia, Inc. Lyxofuranosyl analogues of adenosine
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5055569A (en) 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
PT95628A (pt) 1989-10-19 1991-09-30 Searle & Co Metodo de tratamento de perturbacoes de mobilidade gastrointestinal com composto de adenosina
BR9105935A (pt) 1990-01-11 1992-11-17 Isis Pharmaceuticals Inc Composicao,analogo de oligonucleotideo,oligonucleotideo sequenciado misto,processo para a preparacao de nucleosideos 2'-substituidos,composicao para modular a atividade de rna,processos para modular a producao de uma proteina por um organismo,para tratar um animal,para detectar a presenca ou ausencia de rna,oligonucleotideo ou analogo de analogo de oligonucleotideo resistente a nuclease e processo para tratar um organismo tendo uma doenca
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5280015A (en) * 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
ATE147074T1 (de) * 1990-09-25 1997-01-15 Rhone Poulenc Rorer Int Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen
CA2100863A1 (fr) 1991-01-23 1992-07-24 David A. Bullough Inhibiteurs de l'adenosine-kinase
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
FR2685918B1 (fr) 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687678B1 (fr) * 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
MX9301943A (es) 1992-04-02 1994-08-31 Smithkline Beecham Corp Compuestos.
US5424297A (en) * 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
AU4772493A (en) 1992-07-15 1994-02-14 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Sulfo-derivatives of adenosine
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995018817A1 (fr) 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
KR100430207B1 (ko) 1994-06-15 2004-07-19 더 웰컴 파운데이션 리미티드 효소억제제
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
JPH11505702A (ja) * 1995-05-18 1999-05-25 コールター インターナショナル コーポレイション アッセイ試薬及び前記アッセイ試薬の製造及び使用方法
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5789589A (en) 1996-04-22 1998-08-04 Drug Innovation & Design, Inc. Guanine analog phosphates
AU3255097A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
WO1998016539A1 (fr) 1996-10-14 1998-04-23 Novo Nordisk A/S Nouveaux derives d'adenosine a action therapeutique
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
WO1998030900A2 (fr) * 1997-01-06 1998-07-16 Klaus Trier Aps Procede de selection
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
PE20000270A1 (es) 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
JP2002506856A (ja) 1998-03-14 2002-03-05 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング フタラジノンｐｄｅｉｉｉ／ｉｖ阻害剤
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
BR9911482A (pt) 1998-06-23 2002-01-22 Glaxo Group Ltd Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
MY121142A (en) 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
WO2000066590A2 (fr) 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Composes modulateurs de recepteur de progesterone tetracycliques et procedes
JP4324338B2 (ja) * 1999-07-02 2009-09-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合イミダゾール化合物及び糖尿病治療薬
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6263209B1 (en) 1999-07-28 2001-07-17 Motorola, Inc. Method and apparatus in a wireless communication system for creating a learning function
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
US6803457B1 (en) * 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
CN1404481A (zh) 2000-01-31 2003-03-19 辉瑞产品公司 用作pde4同功酶选择性抑制剂的烟酰胺苯并稠合的杂环衍生物
TR200402292T4 (tr) * 2000-01-31 2004-12-21 Pfizer Products Inc. PDE4 izozimlerinin inhibitörleri olarak pirimidin karboksamidler.
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6710086B1 (en) * 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6753322B2 (en) * 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
US6921753B2 (en) * 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0016002D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
PL362711A1 (en) 2000-09-29 2004-11-02 Glaxo Group Limited Morpholin-acetamide derivatives for the treatment of inflammatory diseases
AU2002210761A1 (en) 2000-11-03 2002-05-15 Glaxo Group Limited Method of determining susceptibility to diseases
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
DE10064997A1 (de) * 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
BR0206492A (pt) 2001-01-16 2004-02-10 Can Fite Biopharma Ltd Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em células
US7250518B2 (en) * 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
EP1229034B1 (fr) 2001-01-31 2005-04-13 Pfizer Products Inc. Derivés du nicotinamide et leur mimetiques actifs comme ihibiteurs de PDE4 isozymes
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
GB0104555D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
ES2288543T3 (es) 2001-03-08 2008-01-16 Glaxo Group Limited Agonistas de beta-adrenorreceptores.
AU2002238748A1 (en) 2001-03-12 2002-09-24 Glaxo Group Limited Pharmaceutical aerosol formulation
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
DK1373259T3 (da) 2001-03-30 2005-03-29 Pfizer Prod Inc Pyridazinonaldosereduktaseinhibitorer
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US6903109B2 (en) * 2001-04-18 2005-06-07 Ortho-Muniel Pharmaceutical, Inc. Arylindenopyridines and related therapeutic and prophylactic methods
GB0120124D0 (en) * 2001-05-04 2001-10-10 Aventis Pharm Prod Inc Effect of timing and duration of administration of amp 579 on reperfusion injury in rabbit heart
CA2448086A1 (fr) 2001-05-25 2002-12-05 Pfizer Limited Combinaison d'agoniste de recepteur d'adenosine a2a et d'agent anticholinergique permettant de traiter des maladies obstructives des voies aeriennes
US20030013675A1 (en) 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US7262176B2 (en) * 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
JP4191034B2 (ja) 2001-09-14 2008-12-03 グラクソ グループ リミテッド 呼吸器疾患の治療のためのフェネタノールアミン誘導体
NZ545787A (en) 2001-10-01 2007-12-21 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
CA2462525A1 (fr) * 2001-10-31 2003-05-08 Merck Patent Gesellschaft Mit Beschraenkter Haftung Inhibiteurs de la phosphodiesterase de type 4 et leurs utilisations
WO2003039528A1 (fr) 2001-11-02 2003-05-15 Aventis Pharmaceuticals Inc. Composition pharmaceutique comprenant un agoniste d'adenosine a1/a2 et un inhibiteur d'echangeur sodium-hydrogene
EP1441730B1 (fr) * 2001-11-05 2006-08-09 Merck Patent GmbH Hydrazono-malonitriles
WO2003042160A1 (fr) 2001-11-13 2003-05-22 Theravance, Inc. Agonistes de recepteur d'aryl aniline beta-2 adrenergique
US6911453B2 (en) * 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6703405B2 (en) * 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
WO2003059899A1 (fr) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques de glucocorticoides, procedes de fabrication, preparations pharmaceutiques renfermant ces mimetiques et utilisations
WO2003062256A1 (fr) 2002-01-17 2003-07-31 Ribapharm Inc. Analogues d'adenosine 2'-beta-modifiee-6-substituee et leur utilisation en tant qu'agents antiviraux
EP1467730A4 (fr) 2002-01-22 2010-03-10 Univ California Ligands non steroidiens pour le recepteur des corticoides, compositions et utilisations desdits ligands
EP1469864A1 (fr) 2002-01-25 2004-10-27 Muscagen Limited Composes utilises en tant qu'agonistes des recepteurs a-3 de l'adenosine
US6756392B2 (en) * 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
EA008939B1 (ru) * 2002-02-11 2007-10-26 Пфайзер Инк. Производные никотинамида, полезные в качестве ингибиторов pde4
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
KR20040093155A (ko) 2002-03-18 2004-11-04 야마노우치세이야쿠 가부시키가이샤 흡입용 분말 의약조성물 및 이의 제조방법
WO2003080053A1 (fr) * 2002-03-18 2003-10-02 Schering Corporation Traitements combines pour maladies induites par la chimiokine
GB0206655D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel process
GB0206657D0 (en) 2002-03-21 2002-05-01 Glaxo Group Ltd Novel intermediate and process
AU2003230700A1 (en) 2002-03-26 2003-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
RS51097B (sr) 2002-03-26 2010-10-31 Boehringer Ingelheim Pharmaceuticals Inc. Glukokortikoidni mimetici,postupci za njihovo dobijanje, farmaceutski preparati i njihova primena
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
CA2481320A1 (fr) 2002-04-11 2003-10-23 Merck & Co., Inc. Derives de 1h-benzo[f]indazol-5-yl utilises en tant que modulateurs selectifs du recepteur glucocorticoide
GB0208608D0 (en) 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
AU2003222841A1 (en) 2002-04-25 2003-11-10 Glaxo Group Limited Phenethanolamine derivatives
AU2003251303A1 (en) 2002-05-21 2003-12-12 Glaxo Group Limited Pharmaceutical products and methods of manufacture
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BR0312575A (pt) 2002-07-08 2005-05-03 Pfizer Prod Inc Moduladores do receptor de glicocorticóides
DE60331103D1 (de) 2002-07-18 2010-03-11 Bristol Myers Squibb Co Zusammensetzungen und verfahren im zusammenhang mit der nuklearen hormon-rezeptor-stelle ii
US6995181B2 (en) 2002-07-18 2006-02-07 Bristol-Myers Squibb Co. Modulators of the glucocorticoid receptor and method
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
WO2004018429A2 (fr) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
US20050113302A1 (en) 2002-08-29 2005-05-26 Thompson John F. A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
WO2004022573A2 (fr) 2002-09-09 2004-03-18 Cv Therapeutics, Inc. Agonistes du recepteur de l'adenosine a3
US7112572B2 (en) * 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
KR20050057294A (ko) 2002-09-09 2005-06-16 트라이젠 리미티드 보론산 염, 및 혈전증의 치료를 위한 그것의 용도
SI1545587T1 (sl) * 2002-09-16 2011-06-30 Agennix Inc Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede
PL375993A1 (en) 2002-09-16 2005-12-12 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
JP4520309B2 (ja) 2002-09-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション 選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−２−Ｈ−ナフト［１，２−ｆ］インドール−４−カルボキサミド誘導体
US20040229780A1 (en) * 2002-09-20 2004-11-18 Olivera Baldomero M. KappaM-conopeptides as organ protectants
AU2003270752A1 (en) 2002-09-27 2004-04-19 King Pharmaceuticals Research And Development, Inc. A method to demonstrate the efficacy of pharmacological stress agent
US20060100168A1 (en) 2002-09-30 2006-05-11 The Trustee Of Boston University Method of treating cancer using adenosine and its analogs
ATE422203T1 (de) * 2002-10-09 2009-02-15 Schering Corp Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden
US6844362B2 (en) * 2002-10-11 2005-01-18 Pfizer Inc Indole derivatives useful for the treatment of diseases
ES2302938T3 (es) 2002-10-11 2008-08-01 Pfizer Inc. Derivados de indol como agonistas beta-2.
EP1407769A1 (fr) 2002-10-11 2004-04-14 Pfizer Limited Derivés d'indole comme beta-2 agonistes
US20060205790A1 (en) 2002-10-22 2006-09-14 Coe Diane M Medicinal arylethanolamine compounds
AU2003301589A1 (en) 2002-10-25 2004-05-13 Ewha Womans University Purine nucleosides
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
AU2003286143A1 (en) 2002-10-28 2004-05-13 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
MXPA05005895A (es) 2002-12-03 2006-02-08 Vela Pharmaceuticals Inc Composicion farmaceutica de 1-(3, 4-dimetoxifenil)-4 -metil-5-etil -7-metoxi-8 -hidroxi- 5h-2, 3-benzodiacepina y usos de la misma.
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
CA2451267A1 (fr) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
EP1587512A2 (fr) 2003-01-14 2005-10-26 ALTANA Pharma AG Inhibiteurs de pde4 pour le traitement des neoplasmes des cellules lymphoides
US20040166574A1 (en) 2003-02-25 2004-08-26 Antonius John I. Microorganism
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
EP1460064A1 (fr) 2003-03-14 2004-09-22 Pfizer Limited Derivés de Indole-2-carboxamide comme beta-2 agonistes
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
US20040258740A1 (en) * 2003-04-10 2004-12-23 Nene Labs Transdermal delivery composition
CA2522666A1 (fr) 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Polytherapies
US7268147B2 (en) * 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
EP1477167A1 (fr) 2003-05-15 2004-11-17 Pfizer Limited Dérivés de [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl come agonistes de beta2
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
US7375100B2 (en) * 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
CA2527334A1 (fr) 2003-06-04 2004-12-16 Pfizer Inc. Derives de 2-amino-pyridine utiles comme agonistes de recepteurs beta-2 adrenergiques
US7067541B2 (en) * 2003-06-04 2006-06-27 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
WO2004110454A1 (fr) 2003-06-13 2004-12-23 Ishihara Sangyo Kaisha, Ltd. Composition de traitement ou de prevention de maladies necessitant l'administration d'un agoniste du recepteur a2a de l'adenosine
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
GB0317471D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Novel compounds
GB0317484D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
GB0317472D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US20050020587A1 (en) * 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
GB0317509D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7132435B2 (en) * 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317516D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317498D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Compounds
GB0317951D0 (en) 2003-07-31 2003-09-03 Trigen Ltd Compounds
US7511133B2 (en) 2003-09-18 2009-03-31 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor agonists

Also Published As

Publication number Publication date
EP1756120B1 (fr) 2012-05-02
MXPA06013627A (es) 2007-02-28
AR049384A1 (es) 2006-07-26
US7737126B2 (en) 2010-06-15
JP5007225B2 (ja) 2012-08-22
EP1756120A1 (fr) 2007-02-28
ATE556080T1 (de) 2012-05-15
JP2008500378A (ja) 2008-01-10
NO20065757L (no) 2006-12-13
ES2383604T3 (es) 2012-06-22
IL179009A0 (en) 2007-03-08
PE20060272A1 (es) 2006-05-22
CA2566863A1 (fr) 2005-12-08
US20080132526A1 (en) 2008-06-05
AU2005247601A1 (en) 2005-12-08
BRPI0511424A (pt) 2007-12-11
RU2006141276A (ru) 2008-06-27
WO2005116037A1 (fr) 2005-12-08

Similar Documents

Publication Publication Date Title
MA28611B1 (fr) Derive de purine
NL1031741A1 (nl) Purinederivaten.
MA28824B1 (fr) Derives de pyrimidine
ATE553079T1 (de) Heteroarylphenylharnstoffderivat
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
DK1725553T3 (da) Tetrahydropyridoindolderivater
DK1761541T3 (da) Pyrrazolo-pyrimidin-derivater
ATE540935T1 (de) Chinazolinderivate
ATE512960T1 (de) Pyrimidinderivate
DK1928882T3 (da) (s)-n-methylnaltrexon
DK2194043T3 (da) Fremgangsmåder
ATE417830T1 (de) Sulfonylbenzimidazolderivate
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
SE0500299L (sv) Hydroformningsenhet
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
DK1765844T3 (da) Purin-nukleotidderivater
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
ATE430142T1 (de) Phenylpiperazin-methanon-derivate
DK1971588T3 (da) Tiglien-3-onderivater
ATE404542T1 (de) 4-phenylpyrimidin-2-carbonitrilderivate
ATE365731T1 (de) 4-amino-5-cyanopyrimidinderivate
ATE541837T1 (de) Oxaphenanthren-derivate
DE112006001399A5 (de) Baueinheit
DE602006019209D1 (de) Fluoroalkylpyrrolidin-derivate
ZA200609539B (en) Purine derivative